MDR1変異を持つ猫、人気のある薬に重篤な反応を示す危険性(Cats with MDR1 mutation at risk of severe reactions to popular medication)

ad

2024-03-28 ワシントン州立大学(WSU)

MDR1変異を持つ猫、人気のある薬に重篤な反応を示す危険性(Cats with MDR1 mutation at risk of severe reactions to popular medication)
Photo by Travelarium on iStock.

アメリカでは、一部の猫用寄生虫予防薬に含まれる有効成分により、50万匹以上の猫が神経反応を示し、死に至ることもあるリスクに晒されています。これは、ワシントン州立大学の研究によって明らかにされました。特定の遺伝子変異を持つ猫は、薬剤が脳に影響を与える可能性があるため、これらの製品に対して高いリスクを抱えています。FDAの介入と警告ラベルの検討が求められています。

<関連情報>

エプリノメクチンを含む寄生虫駆除剤を標識用量で投与すると、ABCB11930_1931del TCホモ接合体のネコで神経毒性症を引き起こす Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC

Katrina L. Mealey, Neal S. Burke, Nicolas F. Villarino, Michael H. Court, Jennifer P. Heusser
Journal of Veterinary Pharmacology and Therapeutics  Published: 17 February 2024
DOI:https://doi.org/10.1111/jvp.13431

Abstract

The feline MDR1 mutation (ABCB11930_1931delTC) has been associated with neurological toxicosis after topical application of eprinomectin products labeled for feline use. Information was collected from veterinarians who submitted samples for ABCB11930_1931delTC genotyping. In most cases, the submission form indicated an adverse event involving eprinomectin, in other cases submitting veterinarians were contacted to determine whether the patient had experienced an adverse drug event involving eprinomectin. If so, additional information was obtained to determine whether the case met inclusion criteria. 14 cases were highly consistent with eprinomectin toxicosis. Eight cats were homozygous for ABCB11930_1931del TC (3 died; 5 recovered). Six cats were homozygous wildtype (2 died; 4 recovered). The observed ABCB11930_1931delTC frequency (57%) was higher than the expected frequency (≤1%) in the feline population (Fisher Exact test, p < .0001). Among wildtype cats, four were concurrently treated with potential competitive inhibitors of P-glycoprotein. Results indicate that topical eprinomectin products, should be avoided in cats homozygous for ABCB11930_1931delTC. This is a serious, preventable adverse event occurring in an identifiable subpopulation treated with FDA-approved products in accordance with label directions. Acquired P-glycoprotein deficiency resulting from drug interactions may enhance susceptibility to eprinomectin-induced neurological toxicosis in any cat, regardless of ABCB1 genotype.

有機化学・薬学
ad
ad
Follow
ad
タイトルとURLをコピーしました